7.2 Regulatory Actions and Compliance

Ensuring Compliance: The FDA BIMO Program

The FDA's Bioresearch Monitoring (BIMO) program is a comprehensive, agency-wide framework of on-site inspections and data audits designed to monitor all aspects of the conduct and reporting of FDA-regulated research. The BIMO program's primary objectives are to protect the rights, safety, and welfare of human research subjects and to verify the accuracy and reliability of clinical trial data submitted to the FDA in support of research or marketing applications.

BIMO inspections can target Clinical Investigators (the principal investigator at a site), Sponsors, Contract Research Organizations (CROs), and Institutional Review Boards (IRBs). Inspections are generally classified into two categories:

• Routine Inspections (Study Oriented): These are typically scheduled after a sponsor submits an NDA, BLA, or PMA. The FDA selects specific clinical sites for inspection based on high enrollment numbers, high efficacy results, or anomalous data compared to other sites.
• For-Cause Inspections (Investigator Oriented): These are initiated in response to a specific problem or complaint. Triggers include reports of serious protocol violations, suspicion of fraud, numerous subject complaints, or significant discrepancies identified during sponsor monitoring.

---

The Inspection Process and Form FDA 483

When FDA investigators arrive at a clinical site, they present their credentials and a Form FDA 482 (Notice of Inspection). The Principal Investigator (PI) and the research team must cooperate fully, providing access to all study-related records, including source documents, CRFs, regulatory binders, and investigational product accountability logs.

At the conclusion of the inspection, the FDA investigators conduct a close-out meeting with the PI. If the investigators observed conditions that, in their judgment, may constitute violations of the Food Drug and Cosmetic (FD&C) Act or related regulations, they will issue a Form FDA 483 (Inspectional Observations).

Understanding Form FDA 483

A Form FDA 483 is not a final FDA determination of a violation; it represents the observations made by the investigator during the inspection. Common observations cited on Form 483s include:

• Failure to follow the investigational plan (protocol deviations/violations).
• Inadequate and inaccurate records (source documentation discrepancies).
• Inadequate drug/device accountability.
• Failure to obtain proper informed consent.
• Failure to report adverse events promptly.

While not legally required, it is highly recommended that the PI submit a written response to the Form FDA 483 within 15 business days. This response should acknowledge the observations, provide a root cause analysis for the issues, and detail the Corrective and Preventive Actions (CAPA) implemented to prevent recurrence.

---

Warning Letters and Severe Regulatory Actions

After reviewing the Establishment Inspection Report (EIR) and the site's response to the Form 483, the FDA determines the final classification of the inspection. If the observations are severe and represent a significant risk to subject safety or data integrity, the FDA may issue a Warning Letter.

Warning Letters

A Warning Letter is a formal, public notification from the FDA indicating that the agency has found significant violations. It demands immediate and comprehensive corrective action. The PI typically has 15 working days to respond to a Warning Letter in writing, outlining the specific steps taken to correct the violations and prevent them from happening again.

Unlike a Form 483, a Warning Letter is posted publicly on the FDA's website. It can severely damage a site's reputation and make sponsors hesitant to select the site for future trials.

Disqualification and Debarment

In extreme cases of repeated noncompliance, fraud, or deliberate falsification of data, the FDA can initiate proceedings to disqualify an investigator. A disqualified investigator is no longer eligible to receive investigational drugs, biologics, or devices. Furthermore, individuals convicted of a felony related to the development or approval of a drug or device can be debarred, precluding them from providing any services in any capacity to a person that has an approved or pending drug product application.

---

Corrective and Preventive Actions (CAPA)

Whether responding to a sponsor audit finding, an IRB concern, or an FDA Form 483, clinical sites must utilize a Corrective and Preventive Action (CAPA) plan. A strong CAPA is the cornerstone of a site's quality management system.

• Corrective Action: Action taken to eliminate the cause of an existing nonconformity, defect, or other undesirable situation to prevent recurrence. (e.g., Retraining a coordinator who missed an essential protocol procedure).
• Preventive Action: Action taken to eliminate the cause of a potential nonconformity, defect, or other undesirable situation to prevent occurrence. (e.g., Implementing a new checklist for all coordinators to ensure the missed procedure is not skipped by anyone in the future).

A robust CAPA involves a thorough Root Cause Analysis (RCA). Instead of simply blaming "human error," the site must dig deeper to understand why the error occurred. Was the protocol overly complex? Was the training inadequate? Was the site understaffed? Addressing the root cause is the only way to ensure preventive actions are effective.

---

Clinical Holds

A Clinical Hold is an order issued by the FDA to a sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation.

The FDA may place a clinical hold for several reasons:

• Safety Concerns: Subjects are or would be exposed to an unreasonable and significant risk of illness or injury.
• Investigator Qualifications: The clinical investigators are not qualified by scientific training or experience to conduct the investigation.
• Protocol Deficiencies: The investigator's brochure is misleading, erroneous, or materially incomplete, or the protocol is deficient in design.

When a clinical hold is issued, no new subjects may be enrolled, and subjects already in the study must be taken off the investigational product unless the FDA permits them to continue for safety reasons. The sponsor must address the FDA's concerns completely and receive written notification that the hold is lifted before the trial can resume. The CCRC plays a vital role during a clinical hold by ensuring all current subjects are managed safely and according to the modified, FDA-approved plan during the suspension.